ArticleAnnals of hematology2022

The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.

David Dingli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.